Armenia, Daniele Bouba, Yagai Gagliardini, Roberta Fabeni, Lavinia Borghi, Vanni Berno, Giulia Vergori, Alessandra Cicalini, Stefania Mussini, Cristina Antinori, Andrea
...
Published in
HIV medicine
We evaluated the virological response and resistance profile in combined antiretroviral therapy (cART)-experienced HIV-1-infected patients starting a dual therapy with dolutegravir (DTG) and boosted darunavir (bDRV) for the first time. Survival analyses were used to evaluate virological success (VS) and virological rebound (VR) in viraemic and viro...
Di Castelnuovo, Augusto Costanzo, Simona Antinori, Andrea Berselli, Nausicaa Blandi, Lorenzo Bonaccio, Marialaura Bruno, Raffaele Cauda, Roberto Gialluisi, Alessandro Guaraldi, Giovanni
...
Published in
Frontiers in Medicine
Background: Protease inhibitors have been considered as possible therapeutic agents for COVID-19 patients. Objectives: To describe the association between lopinavir/ritonavir (LPV/r) or darunavir/cobicistat (DRV/c) use and in-hospital mortality in COVID-19 patients. Study Design: Multicenter observational study of COVID-19 patients admitted in 33 I...
Dunn, Keith Rogers, Rachel Simonson, Richard Bruce Luo, Donghan Sheng, Shubin Kassam, Purnima T Seyedkazemi, Sareh Hardy, Hélène
Published in
HIV research & clinical practice
Treatment during acute or early human immunodeficiency virus (HIV)-1 infection is associated with immunologic and virologic benefits. To evaluate darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) efficacy/safety among patients with acute or early HIV-1 infection who rapidly initiate treatment. DIAMOND (ClinicalTrials.gov Identifi...
Negrut, Nicoleta Codrean, Adriana Hodisan, Ioana Bungau, Simona Tit, Delia Mirela Marin, Ruxandra Behl, Tapan Banica, Florin Diaconu, Camelia C. Nistor-Cseppento, Delia Carmen
...
Published in
Experimental and Therapeutic Medicine
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is responsible for generating a global effort to discover urgent therapeutic solutions to limit the human damage caused by COVID-19. In the period of April to June 2020, 105 patients diagnosed with COVID-19 met the conditions for inclusion in the present study. They were trea...
Orkin, Chloe Elion, Richard Thompson, Melanie Rockstroh, Juergen K Alvarez Bognar, Fernando Xu, Zhi J Hwang, Carey Sklar, Peter Martin, Elizabeth A
Published in
AIDS (London, England)
To evaluate changes in weight and BMI in adults with HIV-1 at 1 and 2 years after starting an antiretroviral regimen that included doravirine, ritonavir-boosted darunavir, or efavirenz. Post-hoc analysis of pooled data from three randomized controlled trials. We evaluated weight change from baseline, weight gain at least 10%, and increase in BMI af...
Huhn, Gregory D Crofoot, Gordon Ramgopal, Moti Gathe, Joseph Bolan, Robert Luo, Donghan Simonson, Richard Bruce Nettles, Richard E Benson, Carmela Dunn, Keith
...
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Most guidelines recommend rapid treatment initiation for patients with newly diagnosed human immunodeficiency virus type 1 (HIV-1) infection, but prospective US data are limited. The DIAMOND (NCT03227861) study using darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is a phase 3 prospective study evaluating effi...
Chaussade, Hélène Tumiotto, Camille Le Marec, Fabien Leleux, Olivier Lefèvre, Lucile Lazaro, Estibaliz Lafon, Marie-Edith Nyamankolly, Elsa Duffau, Pierre Neau, Didier
...
Published in
Open Forum Infectious Diseases
A low level of darunavir resistance-associated mutation emergence in patients with virological failure during long term use of boosted darunavir. Confirmation of the robustness of this protease inhibitor in the ANRS CO3 Aquitaine cohort in a real life setting.
Liu, Zhanglong Tran, Trang T. Pham, Linh Hu, Lingna Bentz, Kyle Savin, Daniel A. Fanucci, Gail E.
Published in
Viruses
Multidrug resistance continues to be a barrier to the effectiveness of highly active antiretroviral therapy in the treatment of human immunodeficiency virus 1 (HIV-1) infection. Darunavir (DRV) is a highly potent protease inhibitor (PI) that is oftentimes effective when drug resistance has emerged against first-generation inhibitors. Resistance to ...
Darwish, Ibrahim A. Almehizia, Abdulrahman A. Radwan, Awwad A. Herqash, Rashed N.
Published in
Molecules
Darunavir (DRV) is a potent antiviral drug used for treatment of infections with human immunodeficiency virus (HIV). Effective and safe treatment with DRV requires its therapeutic drug monitoring (TDM) in patient’s plasma during therapy. To support TDM of DRV, a specific antibody with high affinity is required in order to develop a sensitive immuno...
Spinner, Christoph D Kümmerle, Tim Schneider, Jochen Cordes, Christiane Heiken, Hans Stellbrink, Hans-Jürgen Krznaric, Ivanka Scholten, Stephan Jensen, Björn Wyen, Christoph
...
Published in
Open Forum Infectious Diseases
The DUALIS phase-III study demonstrated non-inferiority of an effective and safe switch to dolutegravir combined with boosted darunavir (2DR) in suppressed people living with HIV as compared to continue 2 nucleoside reverse transcriptase inhibitors in combination with boosted darunavir (3DR).
